ArticleCancer gene therapy2002
Efficient genetic modification of murine dendritic cells by electroporation with mRNA.
Article in Cancer gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 114 citations in OpenAlex.
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.Journal for immunotherapy of cancer · 2025Article
- The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs.Molecular therapy. Nucleic acids · 2024Article
- Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy.Biomaterials research · 2024Review
- mRNA as a medicine in nephrology: the future is now.Clinical kidney journal · 2023Review
- Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8Theranostics · 2023Article
- Effect of Experimental Electrical and Biological Parameters on Gene Transfer by Electroporation: A Systematic Review and Meta-Analysis.Pharmaceutics · 2022Review
- Recent Advances in Microscale Electroporation.Chemical reviews · 2022Review
- Efficient Induction of Antigen-Specific CD8Pharmaceutics · 2022Article
- Transfection by Electroporation of Cancer and Primary Cells Using Nanosecond and Microsecond Electric Fields.Pharmaceutics · 2022Article
- Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro.Molecules (Basel, Switzerland) · 2022Article
- Article
- Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy.Pharmaceutics · 2022Review
- H2-M and H2-O as Targeting Vehicles for the MHC Class II Processing Compartment Promote Antigen-Specific CD4+ T Cell Activation.Vaccines · 2021Article
- Delivery of transcription factors as modulators of cell differentiation.Drug delivery and translational research · 2021Review
- Hybridization Networks of mRNA and Branched RNA Hybrids.Chembiochem : a European journal of chemical biology · 2021Article
- Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.Pharmaceutics · 2020Review
- High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing.Scientific reports · 2020Article
- Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- mRNA as novel technology for passive immunotherapy.Cellular and molecular life sciences : CMLS · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, human dendritic cells (DCs) pulsed with mRNA encoding a broad range of tumor antigens have proven to be potent activators of a primary anti-tumor-specific T-cell response in vitro. The aim of this study was to improve the mRNA pulsing of murine DC. Compared to a standard lipofection protocol and passive pulsing, electroporation was, in our hands, the most efficient method. The optimal conditions to electroporate murine bone marrow-derived DCs with mRNA were determined using enhanced green fluorescent protein and a truncated form of the nerve growth factor receptor. We could obtain high transfection efficiencies around 70-80% with a mean fluorescence intensity of 100-200. A maximal expression level was reached 3 hours after electroporation. A clear dose-response effect was seen depending on the amount of mRNA used. Importantly, the electroporation process did not affect the viability nor the allostimulatory capacity or phenotype of the DC. To study the capacity of mRNA-electroporated DCs to present antigen in the context of MHC classes I and II, we made use of chimeric constructs of ovalbumin. The dose-dependent response effect and the duration of presentation were also determined. Together, these results demonstrate that mRNA electroporation is a useful method to generate genetically modified murine DC, which can be used for preclinical studies testing immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.